Влияние комбинированной антигипертензивной терапии на плазменный, сосудисто-тромбоцитарный гемостаз и перекисное окисление липидов у больных артериальной гипертензией с метаболическим синдромом

The impact of antihypertensive therapy with the angiotensin-converting enzyme inhibitor enalapril (enap) and with enalapril in combination with the long-acting calcium channel blocker verapamil SR (isoptin SR) on changes of plasmatic, vascular-thrombocytic hemostasis and lipid peroxidation in patients with metabolic syndrome and arterial hypertension was studied. Combined therapy with enalapril and verapamil significantly reduces the fasting glucose and glycated hemoglobin concentrations, the aggregation activity of thrombocytes in the patient's blood, inhibits the lipid peroxidation, increases the level of high-density lipoprotein cholesterol, and decreases the coefficient of atherogenecity. Combined therapy with enalapril and verapamil SR can be recommended for treatment of arterial hypertension in patients with metabolic syndrome.Изучено влияние антигипертензивной терапии ингибитором ангиотензинпревращающего фермента эналаприлом (энап) и эналаприлом в комбинации с блокатором кальциевых каналов верапамилом СР пролонгированного действия (изоптин СР) на динамику плазменного, сосудисто-тромбоцитарного гемостаза и перекисного окисления липидов (ПОЛ) у больных метаболическим синдромом, осложненным артериальной гипертензией (АГ). Комбинированное применение эналаприла и верапамила достоверно уменьшает в крови больных концентрацию глюкозы натощак, содержание гликированного гемоглобина, агрегационную активность тромбоцитов, подавляет ПОЛ, повышает содержание холестерина липопротеинов высокой плотности, снижает коэффициент атерогенности. Комбинированная терапия эналаприлом и верапамилом СР может быть рекомендована для лечения АГ у больных метаболическим синдромом

Influence of a binder on the electrochemical behaviour of Si/RGO composite as negative electrode material for Li-ion batteries

Received: 02.12.2020. Accepted: 21.12.2020. Published:30.12.2020.A composite consisting of silicon nanoparticles and reduced graphene oxide nanosheets (Si/RGO) was studied as a promising material for the negative electrode of lithium-ion batteries. Commonly used polyvinylidene fluoride (PVdF) and carboxymethyl cellulose (CMC) served as a binder. To reveal the influence of the binder on the electrochemical behaviour of the Si/RGO composite, binder-free electrodes were also prepared and examined. Anode half-cells with composites comprising CMC as a binder demonstrated the best properties: capacity over 1200 mAh·g–1, excellent cycling performance and good rate capability up to 1.0C.This work was performed with financial support from the Ministry of Science and Higher Education of Russian Federation, project ID RFMEFI60419X0235

COMBINED ANTIHYPERTENSIVE THERAPY IN METABOLIC SYNDROME

Aim. To compare effects of enalapril in combination with long-acting nifedipine or moxonidine on blood pressure (BP), myocardial mass and diastolic function of left ventricular, lipid and carbohydrate metabolism, platelet aggregation in patients with arterial hypertension (HT) and metabolic syndrome (MS).Material and methods. 50 patients with HT and MS were examined. 25 patients were treated with enalapril and long-acting nifedipine and 25 patients – with enalapril and moxonidine. 24-hour BP monitoring, echocardiography, anthropometry, lipid and carbohydrate metabolism estimation, platelet aggregation testing were performed before and 6 months after treatment.Results. Both combinations allowed to achieve target BP levels, provided cardioprotective and positive metabolic effects in most patients. The combination of enalapril and long-acting nifedipine had more significant antihypertensive effect and more prominently decreased the platelet aggregation induced by collagen. The combination of enalapril and moxonidine had more significant positive effects on carbohydrate metabolism and ADP-induced platelet aggregation.Conclusion. Enalapril in combination with long-acting nifedipine or moxonidine can be recommended for treatment of patients with HT and MS

Evaluation of the main processing parameters influencing the performance of poly(vinylidene fluoride – trifluorethylene) lithium ion battery separators

Poly(vinylidene fluoride – trifluorethylene) membranes are evaluated for lithium ion battery separator applications. Some of the main parameters affecting separator performance such as porosity, dehydration of lithium ions and processing technique (Li-ion uptake versus composite formation) are investigated. The polymer characteristics, as determined by infrared spectroscopy, do not change as a function of porosity, dehydration of lithium ions in the electrolyte solution or processing technique. The electrochemical impedance spectroscopy represented through the Nyquist plot, Bode plot and the ionic conductivity as a function of temperature, strongly depends on the aforementioned paramenters. The membrane that exhibits the highest ionic conductivity is a porous membrane without dehydration of lithium ions and prepared by the uptake technique. The performance of the membrane for battery applications are therefore strongly influenced both by porosity and processing technique.This work is funded by FEDER funds through the "Programa Operacional Factores de Competitividade – COMPETE" and by national funds by FCT- Fundação para a Ciência e a Tecnologia, project references Projects PTDC/CTM/69316/2006, project nºF-COMP-01-0124-FEDER-022716 (refª FCT PEst-C/QUI/UI0686/2011) and NANO/NMed-SD/0156/2007, and grants SFRH/BD/68499/2010 (C.M.C) and SFRH/BPD/63148/2009 (V.S.). The authors thank Celgard, LLC for kindly supplying their high quality membranes. The authors also thank support from the COST Action MP1003, 2010 ‘European Scientific Network for Artificial Muscles’